Mark Froimson

This profile gathers the share dealings of Mark Froimson in Pacira BioSciences, Inc., where the filings describe the role as board member. We count 9 filings; the first trade dates from 9 June 2021 and the latest from 17 March 2026.

The open-market side counts 1 purchase for €15k alongside 2 sales for €66k. Sales outweigh purchases by €51k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 5 share grants. 2026 to date brings no purchases and 1 sale.

Most recently, on 19 March 2026, the filings show an open-market sale worth €9,483 in Pacira BioSciences, Inc. The clock since the last published purchase (12 August 2024) now reads 797 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.